{"organizations": [], "uuid": "ee159b7ca15962d0dd9b7be9c966620e7f7a9cb2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/08/06/astrazeneca-sosei-cancer-idUSL5N10H1G420150806", "country": "US", "title": "AstraZeneca widens cancer push with up to $500 mln Heptares deal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "AstraZeneca widens cancer push with up to $500 mln Heptares deal | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-08-06T11:09:00.000+03:00", "replies_count": 0, "uuid": "ee159b7ca15962d0dd9b7be9c966620e7f7a9cb2"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/08/06/astrazeneca-sosei-cancer-idUSL5N10H1G420150806", "ord_in_thread": 0, "title": "AstraZeneca widens cancer push with up to $500 mln Heptares deal", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON Aug 6 AstraZeneca expanded its push into cancer immunotherapy on Thursday by striking a deal potentially worth more than $500 million with Sosei's biotech unit Heptares, giving it rights to an experimental treatment.\nAstraZeneca said it would pay an initial $10 million for exclusive global rights to HTL-1071, a so-called adenosine A2A receptor antagonist, and could pay more than $500 million if the product is a commercial success.\nThe companies will also collaborate to discover further A2A receptor-blocking compounds for use in cancer immunotherapy.\nAstraZeneca is betting on new cancer treatments to revive its fortunes as older medicines go off patent.\nBritish-based Heptares specialises in work on an important class of proteins known as G-protein-coupled receptors, or GPCRs, which serve as a main conduit for chemicals to get past a cell's membrane and be taken up by a cell.\nIt was acquired by Japan's Sosei in February for up to $400 million.\nThe importance of GPCRs was recognised in 2012 when the Nobel Prize for chemistry was awarded to two American scientists who pioneered research in the field.\n(Reporting by Ben Hirschler ; Editing by David Holmes )", "external_links": [], "published": "2015-08-06T11:09:00.000+03:00", "crawled": "2015-08-06T10:20:17.487+03:00", "highlightTitle": ""}